secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-01-23T23:59:59+00:00
Accession:  0001104659-26-005968
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals prices $22.15/share public offering of ~9.1M shares for ~$188.3M net proceeds
--------------------------------------------------------------------------------

- Upsized public offering of 7,900,677 shares at $22.15/share; underwriters fully exercised 30-day option for 1,185,101 additional shares.
- Expected net proceeds of approximately $188.3 million after underwriting discounts and expenses.
- Net proceeds to fund working capital and R&D for Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa, and asthma trials.
- Offering expected to close on January 23, 2026; Jefferies and Goldman Sachs acted as lead underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926005968/0001104659-26-005968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926005968/tm263501d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-005968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer